Skip to Content


Active Substance: topotecan
Common Name: topotecan
ATC Code: L01XX17
Marketing Authorisation Holder: Beecham Group plc
Active Substance: topotecan
Status: Withdrawn
Authorisation Date: 1997-04-15
Therapeutic Area: Ovarian Neoplasms
Pharmacotherapeutic Group: Antineoplastic agents

Therapeutic Indication

Topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.

The marketing authorisation for Evotopin has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.